18-Month Interim Results of a Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya®) in Multiple Sclerosis Patients in Germany (PANGAEA)

被引：0

作者：

Ziemssen, Tjalf ^{[1
]}

Lorente, Maria Diaz ^{[2
]}

Vollmar, Patrick ^{[2
]}

Meergans, Matthias ^{[3
]}

Tracik, Ferenc Mark ^{[2
]}

Kempcke, Raimar ^{[4
]}

van Lokven, Tom ^{[2
]}

机构：

[1] Univ Clin Dresden, MS Ctr, Dresden, Germany

[2] Novartis Pharma GmbH, Nurnberg, Germany

[3] Novartis Pharma GmbH, Basel, Switzerland

[4] Univ Clin Dresden, Dresden, Germany

来源：

NEUROLOGY | 2013年 / 80卷

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P01185

引用

页数：2

共 50 条

[1] 18-month interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
Ziemssen, T.
Vollmar, P.
Diaz-Lorente, M.
Fuchs, A.
van Lokven, T.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 318 - 318
[2] Study design and first interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
Ziemssen, T.
Meergans, M.
Vollmar, P.
Kempcke, R.
Tracik, F.
van Lokven, T.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 222 - 223
[3] Study design and first results of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA)
Ziemssen, T.
van Lokven, T.
Kempcke, R.
Meergans, M.
JOURNAL OF NEUROLOGY, 2012, 259 : S72 - S72
[4] Study Design and First Results of a Non-Interventional Registry Study To Establish Long-Term Safety and Pharmaco-Economic Data on Fingolimod (Gilenya®) in Multiple Sclerosis Patients in Germany (PANGAEA)
Ziemssen, Tjalf
van Lokven, Tom
Kempke, Raimar
Meergans, Matthias
NEUROLOGY, 2012, 78
[5] Study design of a non-interventional registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients (PANGAEA)
van Lokven, T.
Kempcke, R.
Ziemssen, T.
Meergans, M.
MULTIPLE SCLEROSIS JOURNAL, 2011, 17 : S213 - S214
[6] Interim Results of the PANGAEA and PEARL Studies, Comparing Treatment Satisfaction and Pharmaco-Economic Data of Fingolimod (Gilenya®) and First-Line Therapies in Multiple Sclerosis Patients in Germany
Ziemssen, Tjalf
Vollmar, Patrick
Meergans, Matthias
Tracik, Ferenc Mark
Lorente, Maria Diaz
Neidhardt, Katja
van Lokven, Tom
NEUROLOGY, 2013, 80
[7] First interim results on treatment satisfaction and pharmaco-economic data comparing Fingolimod and first-line therapies in multiple sclerosis patients in Germany (PANGAEA and PEARL)
Ortler, Sonja
Ziemssen, Tjalf
Antonius, van Lokven
Meergans, Matthias
JOURNAL OF NEUROIMMUNOLOGY, 2012, 253 (1-2) : 31 - 32
[8] The immunomodulation and multiple sclerosis epidemiology (IMSE II) study: a Swedish nationwide pharmaco-epidemiological and genetic study focussed on long-term safety and efficacy of fingolimod (Gilenya®)
Nordin, N.
Hillert, J.
Piehl, F.
Svenningsson, A.
Lycke, J.
Fagius, J.
Walentin, F.
Martin, C.
Nilsson, P.
Feltelius, N.
Dahle, C.
Olsson, T.
MULTIPLE SCLEROSIS JOURNAL, 2013, 19 (11) : 445 - 446
[9] The "Immunomodulation and Multiple Sclerosis Epidemiology" (IMSE II) study; A Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of fingolimod (Gilenya®)
Nordin, N.
Holmen, C.
Hillert, J.
Olsson, T.
MULTIPLE SCLEROSIS JOURNAL, 2012, 18 : 95 - 95
[10] PANGAEA: Post-Authorization Non-interventional German sAfety study of GilEnyA in relapsing-remitting multiple sclerosis (RRMS) patients: A 24-month interim analysis of a German five-year fingolimod registry study
Ziemssen, T.
Diaz-Lorente, M.
Fuchs, A.
Cornelissen, C.
JOURNAL OF NEUROLOGY, 2014, 261 : S444 - S444

← 1 2 3 4 5 →